# **PCT**





# INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:
 C12N 15/11, 15/10, C07K 14/47, C12P 21/00, C12Q 1/68, C07K 16/18, G06F 17/30, 17/50

(11) International Publication Number:

WO 99/53051

(43) International Publication Date:

21 October 1999 (21.10.99)

(21) International Application Number:

PCT/IB99/00712

A2

(22) International Filing Date:

9 April 1999 (09.04.99)

(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

(30) Priority Data:

09/057,719 09/069,047 9 April 1998 (09.04.98) 28 April 1998 (28.04.98)

US US

(71) Applicant (for all designated States except US): GENSET [FR/FR]; 24, rue Royale, F-75008 Paris (FR).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): DUMAS MILNE ED-WARDS, Jean-Baptiste [FR/FR]; 8, rue Grégoire-de-Tours, F-75006 Paris (FR). DUCLERT, Aymeric [FR/FR]; 6 ter, rue Victorine, F-94100 Saint-Maur (FR). GIORDANO, Jean-Yves [FR/FR]; 12, rue Duhesme, F-75018 Paris (FR).
- (74) Agents: MARTIN, Jean-Jacques et al.; Cabinet Regimbeau, 26, avenue Kléber, F-75116 Paris (FR).

# Published

Without international search report and to be republished upon receipt of that report.

# (54) Title: 5' ESTS AND ENCODED HUMAN PROTEINS

#### (57) Abstract

The sequences of 5' ESTs derived from mRNAs encoding secreted proteins are disclosed. The 5' ESTs may be to obtain cDNAs and genomic DNAs corresponding to the 5' ESTs. The 5' ESTs may also be used in diagnostic, forensic, gene therapy, and chromosome expression vectors and secretion vectors.

identify a sequence encoding a signal peptide in these nucleic acids. The locations of the complete ORFs are listed in the accompanying Sequence Listing.

SEQ ID NOs. 812-1516 are "incomplete polypeptide sequences" which include a signal peptide. "Incomplete polypeptide sequences" are polypeptide sequences encoded by nucleic acids in which a start codon has been identified but no stop codon has been identified. These polypeptides are encoded by the nucleic acids of SEQ ID NOs. 24-728. The location of the signal peptide, the von Heijne score of the signal peptide, the sequence of the signal-peptide and the proteolytic cleavage site are indicated as described above.

SEQ ID NOs. 1517-1553 are incomplete polypeptide sequences in which no signal peptide has been identified to date. However, it remains possible that subsequent analysis will identify a signal peptide in these polypeptides. These polypeptides are encoded by the nucleic acids of SEQ ID NOs. 729-765.

SEQ ID NOs. 1554-1580 are "complete polypeptide sequences" which include a signal peptide. "Complete polypeptide sequences" are polypeptide sequences encoded by nucleic acids in which a start codon and a stop codon have been identified. These polypeptides are encoded by the nucleic acids of SEQ ID NOs. 766-792. The location of the signal peptide, the von Heijne score of the signal peptide, the sequence of the signal-peptide and the proteolytic cleavage site are indicated as described above..

SEQ ID NOs. 1581-1599 are complete polypeptide sequences in which no signal peptide has been identified to date. However, it remains possible that subsequent analysis will identify a signal peptide in these polypeptides. These polypeptides are encoded by the nucleic acids of SEQ ID NOs.793-811.

SEQ ID NOs. 1600-1622 are nucleic acid sequences in which no open reading frame has been conclusively identified to date. However, it remains possible subsequent analysis will identify an open reading frame in these nucleic acids.

In the accompanying Sequence Listing, all instances of the symbol "n" in the nucleic acid sequences mean that the nucleotide can be adenine, guanine, cytosine or thymine. In some instances the polypeptide sequences in the Sequence Listing contain the symbol "Xaa." These "Xaa" symbols indicate either (1) a residue which cannot be identified because of nucleotide sequence ambiguity or (2) a stop codon in the determined sequence where applicants believe one should not exist (if the sequence were determined more accurately). In some instances, several possible identities of the unknown amino acids may be suggested by the genetic code.

In the case of secreted proteins, it should be noted that, in accordance with the regulations governing Sequence Listings, in the appended Sequence Listing, the full protein (i.e. the protein containing the signal peptide and the mature protein) extends from an amino acid residue having a negative number through a positively numbered C-terminal amino acid residue. Thus, the first amino acid of the mature protein resulting from cleavage of the signal peptide is designated as amino acid

5

10

C) Deletions in the sequence of a consensus contigated 5'EST to derive a preferred nucleic acid fragment are denoted by an "D", followed by a number indicating the first nucleotide position in a specific SEQ ID to be deleted in a string of deleted nucleotides or the position of the deleted nucleotide in the case of a single deleted nucleotide. Then there is a coma followed by number indicating the number of nucleotide(s) deleted from the sequence provided in the sequence ID. For example, SEQ ID NO: 5398; Position of preferred fragments: 56-780; Variant nucleotides D114,5 would indicate that a preferred polynucleotide fragment had the sequence of positions 56 to 780 of SEQ ID NO. 5398, except that the nucleotides in positions 114 to 118 had been deleted in the preferred polynucleotide as compared with the sequence of SEQ ID No. 5398.

The present invention encompasses isolated, purified, or recombinant nucleic acids which consist of, consist essentially of, or comprise a contiguous span of at least 8, 10, 12, 15, 18, 20, 25, 35, 40, 50, 70, 80, 100, 250, or 500 nucleotides in length, to the extent that a contiguous span of these lengths is consistent with the lengths of the particular polynucleotide, of a polynucleotide described in Table II, or a sequence complementary thereto, wherein said polynucleotide described in Table II. The present invention also encompasses isolated, purified, or recombinant nucleic acids which consist of or consist essentially of a polynucleotide described in Table II, or a sequence complementary thereto, wherein said polynucleotide is selected individually or in any combination from the polynucleotides described in Table II. The present invention further encompasses isolated or purified polypeptides which consist of, consist essentially of, or comprise a contiguous span of at least 8, 10, 12, 15, 18, 20, 25, 35, 40, 50, 70, 80, or 100 amino acids encoded by a polynucleotide described in Table II.

Table II

SEQ ID NO.	Positions of Preferred Fragments	Variant nucleotides
35	1-423	S124, s; I135, a; S293, w; I363, a; S377, r; D424, 15
41	1-427	I117, m; S120, r; S124, g; D373, 1; S376, b; S378, b; I427, gggg; D428, 109
43	1-276	S114, m; S118, rg; S123, r; S139, nr; I142, t; D148, 1; D152, 1; I228, t; I276, gg; D277, 136
45	126-420	D1, 125; I420, ggg; D421, 100
46	1-255	S139, r; I145, r; S146, mm; S150, ar; S254, g; D256, 128
48	4-437	D1, 3; S49, a; S55, g; S79, a; S90, a; I437, tetetg
59	1-471	S26, a; S44, t; S48, t; S109, a; S191, t; S200, gc; S203, a; S210, g; S237, a; S240, g; S255, a; S272, a; S277, a; S279, a; S284, t; S297, g; S305, g; S316, a; I471, ggtca
66	1-428	I428, tactgggg



	<del></del>	30		
		S338, c; I341, cccccggg; D342, 218		
805	2-409	D1, 1; S334, d; I409, aggg; D410, 161		
806	5-384	D1, 4; I384, actaa		
807	1-301	S113, a; S117, c; S123, t; D128, 1; D134, 1;		
		S282, g; S284, a; I301, gacggagggg; D302, 70		
808	2-314	D1, 1; S306, g; I314, ggg; D315, 121		
809	1-394	S53, g; S228, n; S272, vk; I301, g; I358, m;		
		S368, nb; S375, w; I383, mm; I388, yt; I394,		
		nhaccggg		
810	6-205	I0, a; D1, 5; I141, t; I205, ggg; D206, 630		
811	6-270	D1, 5; I270, gggg; D271, 115		
1600	1-247	S45, m; S114, k; I122, m; S123, yc; S158, rr;		
		S221, k; I247, ccccaggg		
1601	1-225	S109, bm; S195, m; I225, tgcacggg		
1602	23-245	D1, 22; D138, 1; S139, s; S242, t; S244, g;		
L		I245, g; D246, 13		
1603	1-303	S71, c; D277, 1; I303, ggagggg; D304, 38		
1604	1-242	S47, w; S50, c; S81, h; S85, d; S91, k; S106, r;		
		1242, tgtggg; D243, 50		
1605	2-225	D1, 1; S20, k; S91, c; I225, ggg; D226, 132		
1606	15-293	D1, 14; S156, g; S193, g; I200, t; I293,		
		acaaaggg		
1607	1-361	S323, c; I361, cccca		
1608	1-151	I151, taagggg; D152, 154		
1609	1-242	S55, s; I135, a; S152, h; I242, cagtaggg		
1610	1-196	I151, w; S190, k; I196, cctgtgg		
1611	1-228	S115, k; S174, rk; I228, cgtttggg		
1612	1-221	S108, v; I221, tgatcggg		
1613	1-281	I66, w; I137, a; D282, 79		
1614	1-171	S53, k; S76, k; I80, k; S81, kw; S86, r; S92, k;		
		S126, k; I171, gccgagg		
1615	2-193	D1, 1; S67, c; I121, s; S122, mm; S126, g;		
		S130, r; S146, r; S156, gm; I193, cctca		
1616	1-349	S251, ww; S259, rs; S275, k; I279, w; S285, y;		
	i	S292, y; I320, m; I331, m; I338, w; I341, s;		
1618		I349, accceggg		
1617	1-129	I118, t; D130, 26		
1618	1-184	D9, 1; D185, 1		
1619	1-169	1122, t; 1169, gcccaggg		
1620	1-187	S106, k; S118, m; S122, cg; S132, k; D188, 59		
1621	1-153	D125, 1; I131, ttt; S152, t; I153, gg; D154, 127		
1622	1-400	S43, s; I126, g; I129, y; S353, d; I400, tatat		

# **EXAMPLE 16**

# Categorization of 5' ESTs and Consensus Contigated 5'ESTs

The nucleic acid sequences of the present invention (SEQ ID NOs. 24-811 and 1600-1622) were grouped based on their homology to known sequences as follows. All sequences were compared to EMBL release 57 and daily releases available at the time of filing using BLASTN. All matches with a minimum of 25 nucleotides with 90% homology were retrieved and used to compute Tables IV and V.

20



In some embodiments, 5'ESTs or consensus contigated 5'ESTs nucleic acid sequence do not match any known vertebrate sequence nor any publicly available EST sequence, thus being completely new.

In other embodiments, 5'ESTs or consensus contigated 5'ESTs match a known sequence.

5 Tables III and IV gives for each sequence of the invention in this category referred to by its sequence identification number in the first column, the positions of their preferred fragments in the second column entitled "Positions of preferred fragments." As used herein the term "polynucleotide described in Table III" refers to the all of the preferred polynucleotide fragments defined in Table III in this manner, and the term "polynucleotide described in Table IV" refers to the all of the preferred polynucleotides fragments defined in Table IV in this manner. The present invention encompasses isolated, purified, or recombinant nucleic acids which consist of, consist essentially of, or comprise a contiguous span of at least 8, 10, 12, 15, 18, 20, 25, 35, 40, 50, 70, 80, 100, 250, or 500 nucleotides in length, to the extent that a contiguous span of these lengths is consistent with the lengths of the particular polynucleotide, of a polynucleotide described in Table III or Table IV, or a sequence complementary thereto, wherein said polynucleotide described in Table III or Talbe IV. The present invention also encompasses isolated, purified, or recombinant nucleic acids which consist of or consist essentially of a polynucleotide described in Table IV, or a sequence complementary thereto, wherein said polynucleotide described in Table IV, or a sequence complementary thereto, wherein said polynucleotide described in Table IV, or a sequence complementary thereto, wherein said polynucleotide described in Table IV, or a sequence complementary thereto, wherein said polynucleotide is

Table III

selected individually or in any combination from the polynucleotides described in Table III or Table IV.

SEQ ID	Positions of preferred	
NO	fragments	
24	1-251	
25	1-83	
28	227-276	
29	1-27	
30	130-242, 283-315, 365-461	
32	314-399	
33	89-321	
34	1-38	
35	1-52, 171-222	
36	1-30, 408-441	
37	1-138	
39	115-140	
40	1-97	
41	1-112	
42	1-177	
46	1-38	
48	376-400	
51	400-466	
54	1-259	
55	189-320	

49		
742	217-280	
743	10-275	
747	1-179	
749	2-31, 139-168	
750	349-410	
752	1-119	
753	1-121	
754	1-28	
760	25-175	
761	1-212	
763	8-75	
766	1-59, 102-248, 295-320	
769	53-85	
771	1-370	
774	1-347	
776	1-200	
778	39-342	
779		
	4-28	
780	1-49, 407-472	
781	116-426	
782	1-59	
783	1-53, 219-453	
784	29-53, 219-263, 426-494	
785	99-347, 386-461	
786	2-28	
788	1-279	
789	1-58	
790	226-268	
792	129-218	
794	265-431	
796	5-86	
797	1-34	
799	1-344	
802	46-477	
806	64-384	
807	135-301	
808	2-314	
810	6-39	
1600	1-25	
1601	1-225	
1602	23-139	
1603	1-294	
1606	15-44	
1607	1-361	
1611	85-228	
1612	1-221	
1613	1-221	
1614		
1615	65-171	
1616	2-142	
	1-46	
1617		
	1620 1-187	
1021	1621 1-136	



Table V

SEQ ID NO	Tissue Distribution
24	AA:1
25	S:1
26	P:1
27	W:1
28	P:1
29	S:1
30	P:1
31	P:1
32	P:1
33	P:1
34	AB:1
35	G:3; P:1; S:1; W:3; AA:4
36	P:1
37	S:1
38	Q:1
39	P:1
40	AB:1
41	B:1; C:3; F:1; G:1; H:4; S:2; T:8; W:1; Z:1; AA:3; AC:1; AD:3
42	A:1
43	N:2
44	P:1
45	C:2; K:1; O:1; S:5
46	K:1; S:2; AA:1
47	AA:1
48	C:1; O:1; P:8
49	P:1
50	P:1
51	P:1
52	S:1
53	AA:1
54	T:1
55	P:1
56	P:1
57	P:1
58	P:1
59	P:7; T:2; Z:1
60	R:1
61	C:1
62	P:1
63	F:1
64	AA:1
65	F:1

1615	AA:10
1616	B:4
1617	T:2
1618	K:2; S:8; AA:1
1619	B:2
1620	W:2
1621	H:1; AB:1
1622	H:2

Table VI

Tissue code	Tissue type	
Α	Bone Marrow	
В	Brain	
с	Cancerous prostate	
D	Cerebellum	
E	Colon	
F	Dystrophic muscle	
G	Fetal brain	
H	Fetal kidney	
I	Fetal liver	
J	Heart	
K	Hypertrophic prostate	
L	Kidney	
M	Large intestine	
N	Liver	
0	Lung	
P	Lymph ganglia	
Q	Lymphocytes	
R	Muscle	
S T	Prostate	
	Ovary	
U	Pancreas	
V	Placenta	
W	Spinal cord	
X	Spleen	
Y	Substantia nigra	
Z	Surrenals	
AA	Testis	
AB	Thyroid	
AC	Umbilical cord	
AD	Uterus	

In addition to categorizing the 5' ESTs and consensus contigated 5' ESTs with respect to their tissue of origin, the spatial and temporal expression patterns of the mRNAs corresponding to the 5' ESTs and consensus contigated 5' ESTs, as well as their expression levels, may be determined as described in Example 18 below.

WO 99/53051 712

WO 99/53051	672	PCT/IB99/00712
tatctggctc aacagctaac	caattotoag coaaatgatg aagatgooto tatggtttta goactgagtg gototaacgt cotgottoag gatotottoo gotgottoac cototttact agaagagttt gotgaagta	ctctgatgcc 180
<210> 1617 <211> 155 <212> DNA <213> Homo sapiens <400> 1617		
atacacatat ccatggtttg	tgagaggete etcaetacce gteetgtete tttgtggaca agteaactet ataeaatatt accaaggeet gagge	agaatgtcag 60 tgaagggatt 120 155
<210> 1618 <211> 185 <212> DNA <213> Homo sapiens <400> 1618		
	tettgeteae eettgaettg gaaaaaceag t attetaaaaa tteageteaa tteteaacea t ttaeteeete teetteaatt eeaettteet o	
<210> 1619 <211> 169 <212> DNA <213> Homo sapiens <400> 1619		
	ggagtcctc gctggaggac ccactgcgga g acagtgcta cgactacagc agtatagctc c ccattgtcc tttctaaata cctggaaac	tttgtgcga 60 ggtggcgtg 120 169
<211> 246 <212> DNA <213> Homo sapiens		
<220> <221> misc_feature <222> 122 <223> n=a, g, c or t		
anstgggcag ttttattcac ca	aatttttat cactatotga attattttga ti tootatatt cogttoaatg taagototat ga ataagtatt coaagooota gtggttootg go aagtoaatg accagatgaa tggottttaa ac	agaccaaga 120
<210> 1621 <211> 280 <212> DNA <213> Homo sapiens <400> 1621		
ggccaaagac atttttggac aa	ggatgtga tettggetea eaggggaega tg gttgetgt aactgetget eagteeacea tt gtttaace aegaageega agaeetgtte ta eaceaata ttaetgaaga gaatgteeaa aa etttttaa aggaaeagte	gaggaaca 120
<210> 1622		

INC305090
TCAAAGCATCAAAGTGAGGATAAGCCTAAAATCAGCTCTTGGAGATAAAGCA
TATGANTGGAACGACAATGAAATGTACCTGTTCCGATCATNTGTTGCATATGC
TATGAGGCAGTACTTTTTAAAAAGTAAAAAATCAGATGATTCTTTTTGGGGAG
GAGGATGTGCGAGTGGCTAATTTGAAACCAAGAATCTCCTTTAATTTCTTTGT
CACTGCACCTAAAAATGTGTCTGATATCATTCCTAGAACTGAAGTTGAAAAG
GCCATCAGGATGTCCCGGAGCCGTATCAATGATGCTTTCCGTCTGAATGACA

INC761848
GGAGTGATAGTGGCATTGTCATCCGATCTTCATGGGATCAGAGATCGG
AAGAAGAAAAATAAAGCAAGAAGTGGAGAAAATCCTATGCCTCCATCGTATT
AGCAAAGGAGAAAATAATCCAGGTTCCAAAACACTGATGTGTTCAGACCTCCT
TTTAGAAAAAATTATGTTTTTNCTTTGAGGTGTTTTTTTT

INC1501621 CTGCACCTAAAAATGTGTCTGATATCATTCCTAGAACTGAAGTTGAAAAGGC CATCNGGATGTCCCGGAGCCGTATCAATGATGCTTTCCGTCTGAATGACAAC AGCCTAGAGTTTCTGGGGATACAGCCAACACTTGGACCTCCTAACCAGCCCC

CTGTTTCCATATGGCTGATTGTTTTTGGAG

INC1582746
GTCTAAAGAGAAGAATCCAGGGAACAGGTAGAGGACATTGCTTTTTCACT
TCCAAGGTGCTTGATCAACATCTCCCTGACAACACAAAACTAGAGCCAGGGG
CCTCCGTGAACTCCCAGAGCATGCCTGATAGAAACTCATTTCTACTGTTCTCT
AACTGTGGAGTGAATGGAAATTCCAACTGTATGTTCACCCTCTGAAGTGGGT

ACCCA

ANATGATAAAGATATCATTAAATGTCAAAACTATGACTCTGTTCAGAAAAAA AATTGTCCAAAGACAACATGGCCAAGGAGAGAGCATCTTCATTGACATTGCT TTCAGTATTTATTTCTGTCTCTGGATTTGACTTCTGTTCTGTTTCTTAATAAGG ATTTTGTATTAGAGTATATTAGGGAAAGTGTGTATTTGGTCTCACAGGCTGTT CAGGGATAATCTAAATGTAAATGTCTGTTGAATTCTGAAGTTGAAAACAA

CATGCTTTCTTCACAGTAACTCAGTTCAAGTACTATGGTGATTTGCCTACAGT GATGTTTGGAATCGATCATGCTTTCTTCAAGGTGACAGGTCTAAAGAGAGAA GAATCCAGGGAACAGGTAGAGGACATTGCTTTTTCACTTCCAAGGTGCTTGA TCAACATCTCCCTGACAACACACAAAACTAGAGCCAGGGGCCTCCGTGAACTCC CAGAGCATGCCTGATAGAAACTCATTTCTACTGTTCTC

TGATCTTGGCTCACAGGGGACGATGTCAAGCTCTTCCTGGCTCCTTCTCAGCC TTGTTGNTGTAACTGCTGCTCAGTCCACCATTGAGGAACAGGCCAAGACATTT TTGGACAAGTTTAACCACGAAGCCGAAGACCTGTTCTATCAAAGTTCACTTGC TTCTTGGAATTATAACACCANTATTACTGAAGAGAATGTCCAAAACATGAAT AATGCTGGGGACAAATGGTCTGCCTTTTTAAAGG

CATGAAGGCCCTCTGCACAAATGTGACATCTCAAACTCTACAGAAGCTGGAC AGAAACTGTTCAATATGCTGAGGCTTGGAAAATCAGAACCCTGGACCCTAGC ATTGGAAAATGTTGTAGGAGCAAAGAACATGAATGTAAGGCCACTGCTCAAC TACTTTGAGCCCTTATTTACCTGGCTGAAAGACCAGAACAAGAATTCTTTTGT GGGATGGAGTACCGACTGGAGTCCATATGCAGACCAAAGCATCAAAGTGAG GATAA

ATTCAGTGGATGTGATCTTGGCTCACAGGGGACGATGTCAAGCTCTTCCTGGC TCCTTCTCAGCCTTGTTGCTGTAACTGCTCAGTCCACCATTGAGGAACAG GCCAAGACATTTTTGGACAAGTTTAACCACGAAGCCGAAGACCTGTTCTATC AAAGTTCACTTGCTTCTTGGAATTATAACACCAATATTACTGAAGAGATGTCC AAAACTGAATAATGGCTGGGGACAAATGGTCTGCCTTTTTANAGGAACAGTC CANACTTGNCC INC4179553
CTTGGCTCACAGGGGACGATGTCAAGCNCTTCCTGGCTCCTTCTCAGCCTTGT
TGCTGTAACTGCTCAGTCCACCATTGAGGAACAGGCCAAGACATTTTTGG
ACAAGTTTAACCACGAAGCCGAAGACCTGTTCTATCAAAGTTCACTTGCTTCT
TGGAATTATAACACCAATATTACTGAAGAGAATGTCCAAAACATGAATAATG
CTGGGGACA

INC4179240
GATCTTGGCTCACAGGGGACGATGTCAAGCTCCTTCCTGGCTCCTTCTCAGCC
TTGTTGCTGTAACTGGCTGCTCAGTCCACCATTGAGGAACAGGCCAAGACATT
TTTGGACAAGTTTAACCACGAAGCCGAAGACCTGTTCTATCAAAGTTCACTTG
CTTCTTGGAATTATAACACCAATATTACTGAAGAGAATGTCCAAAACATGAN
TNATGCTGGGGGACAAATGGTCTGCCTTTTTAAAAGGAACAGTCCCAC

TCAGTGGATGAAAAGTGGTGGGAGATGAAGCGAGANATAGTTGGGGTGGT GGGNCCTGTGCCCCATGATGAAACATACTGTGACCCCGCATCTCTGTTCCATG TTTCTAATGATTACTCATTCGATATTACACAAGGACCCTTTACCAATTCC AGTTTCAAGAAGCACTTTGTCAAGCAGCTAAACATGAAGGCCCTCTGCACAA ATGTGACATCTCAAACTCTACAGAAGCTGGACAGAAACTGTTCAATATGCTG AGGCTTGGAAAATCAGAA CCC

GCTCACAGGGGACGATGTCAAGCTCTTCCTGGCTCCTTCTCAGCCTTGTTGCT GTAACTGCTCAGTCCACCATTGAGGAACAGGCCAAGACATTTTTGGACA AGTTTAACCACGAAGCCGAAGACCTGTTCTATCAAAGTTCACTTGCTTCTTGG AATTATAACACCAATATTACTGAAGAGAATGTCCAAAACATGAATAATGCTG GGGACAAATGGTCTGCCTTTTTAAAGGAACAGTCNACACTTGCCCAAATGTA TCCATACAAGAAATTCAGAATCTCACAGTCCAGCTTC

ACTGGTGTAGCTGCAAGGATTGAGAATGGCATGCATTAGCTCACTTTCATTTA ATCCATTGTCAAGGATGACATGCTTTCTTCACAGTAACTCAGTTCAAGTACTA TGGTGATTTGCCTACAGTGATGTTTGGAATCGATCATGCTTTCTTCAAGGTGA CAGGTCTAAAGAGAGAAGAATCCAGGGAACAGGTAGAGGACATTGCTTTTTC ACTTCCAAGGTGCTTGATCAACATCTCCCTGACAACACAAAACTAGAGCCAG GGGCCTCCGTGAACTCCCA

ATTCAGTGGATGTGATCTTGNGCTCACAGGGGACGATGTCAAGCTCTTCCTGG CTCCTTCTGCAGCNTTGTTGCTNTAACTGCTGCTCNGTCCACCATTGAGGAAC AGGCCAAGACATTTTTGGACAAGTTTAACCACGAAGCCGAAGACCTGTTCTA TCAAAGTTCACTTGCTTCTTGGAATTATAACACCAATATTACTGAAGAGAATG TCCAAAACATGAATAATGCTGGGGACAAATGGTCTGCCTTTTA

AAANATCTATGTTTTNCTCTTGAGGTGATTTTGTTGTATGTAAATGTTANTTT CNTGGTATAGANAATNTAAGATGATAAAGATATCATTAAATGTCAAAACTAT GACTCTGTTCAGAAAAAAAATTGTCCAAAGACAACATGGCCAAGGAGAG CATCTTCATTGACATTGCTTTCAGTATTTATTTCTGTCTCTGGATTTGACTTCT GTTCTGTTTCTTAATAAGGNTTTTGTATTAGAGTATATTAGG

GGATTTGACTTCTGTTTCTTAATAAGGATTTTGTATTAGAGTATATTAG GGAAAGTGTGTATNTGGTCTCACAGGCTGTTCAGGGATAATCTAAATGTAAA TGTCTGTTGAATTTCTGAAGTTGANAACAAGGATATATCATTGGAGCAAGTGT TGGATCTCGTATGGAATATGGATGGATCACTTGTAAGGACAGTGCCTGGGAA CTGGTGTAGCTGCAAGGATTGAGAATGGCATGCATTAGCTC INC4598818
CTAAAATCAGCTCTTGGAGATAAAGCATATGAATGGAACGACAATGAAATGT
ACCTGTTCCGATCATCTGTTGCATATGCTATGAGGCAGTACTTTTTAAAAGTA
AAANATCAGATGATTCTTTTTGGGGAGGAGGATGTGCGAGTGGCTAATTTGA
AACCAAGAATCTCCTTTAATTTCTTTGTCACTGCACCTAAAAATGTGTCTGAT
ATCATTCCTAGAACTGAAGTTGAAAAAGGCCATCAGGC

GGAAGGCGACTTCAGGATCCTTATGTGCACAAAGGTGACAATGGACGACTT CCTGACAGCTCATCATGAGATGGGGCATATCCAGTATGATATGGCATATGCT GCACAACCTTTTCTGCTAAGAAATGGAGCTAATGAAGGATTCCATGAAGCTG TTGGGGAAATCATGTCACTTTCTGCAGCCACACCTAAGCATTTAAAATCCATT GGTCTTCTGTCACCCGATTTTCAAGAAGACAATGAAACAGAAATAAACTTCC TGCTCAAACAAGCACTCACGATTGTTGGGACTCTG

EST1061120
TTTGTGTAAATCTAGCATTTATTGAGTGTCTGCTTTGTGCTCAGCACTGCTCAA
ACACTGTGAGCAAATACAAAAGATTTAAGAGACTGGGTACCCACTTCAGAGG
GTGAACATACAGTTGGAATTTCCATTCACTCCACAGTTAGAGAACAGTAGAA
ATGAGTTTCTATCAGGCATGCTCTGGGAGTTCACGGAGGCCCCTGGCTCTAGT
TTTGTGTTGTCAGGGAGATGTTGATCAAGCACCTTGGAAGTGAAAAAGCAAT
GTCCTCTACCTGTTCCCTGGATTCTTCTCTCTTTAGACCTGTCACCTTGAAGAA
AGCATGATCGATTCCAAACATCACTGTAGGCAAATCACCATAGTACTTGAAC
TGAGTTACTGTAAGAA

CTTCACAGTAACTCAGTTCAAGTACTATGGTGATTTTGCCTACAGTGATGTTTGGAATCGATCATGCTTTCAAGGTGACAGGTCTAAAGAGAGAAGAATCCAGGGAACAGGTAGAGGACATTGCTTTTTCACTTCCAAGGTGCTTGATCAACATCTCCCTGACAACACAAAACTAGAGCCAGGGGCCTCCGTGAACTCCCAGAGCATGCCTGATAGAAACTCATTTCTACTGTTCTCTAACTGTGGAGTGAATGGAAATTCCAACTGTATGTTCACCCTCTGAAGTGGGTACCCAGTCT

CTCTTCTGTTTCTTCTGCTTTTTTTTTTTCTTCTCTCAGTGCCCAACCCAA
GTTCAAAGGCTGATGAGAGAGAAAAACTCATGAAGAGATTTTACTCTAGGGA
AAGTTGCTCAGTGGATGGGATCTTGGCGCACGGGGAAAGATGTCCAGCTCCT
CCTGGCTCCTTCTCAGCCTTGTTGCTGTTACTACTGCTCAGTCCCTCACCGAG
GAAAATGCCAAGACATTTTTAAAACAACTTTAATCAGGAAGCTGAAGACCTGT
CTTATCAAAGTTCACTTGCTTCTTGGAATTATAATACTAACATTACTGAAGAA
AATGCCCAAAAGATGAGTGAGGCTGCAGCCAAATGGTCTGCCTTTTATGAAG
AACAGTCTAAGACTGCCCAAAGTTTCTCACTACAAGAAATCCAGACTCCGAT
CATCAAGCGTCAACTACAGGCCCTTCAGCAAAGTGGGTCTTCAGCACTCTCA
GCAGACAAGAACAAACAGTTGAACACAATTCTGAACACCATGAGCACCATTT
ACAGTACTGGAAAAAGTTTGCAACCCAA

TTTTTTTTTTTTGGGTAAATCTAGCATTTATTGAGTGTCTGCTTTGTGCTCAG
CACTGCTCAAACACTGTGAGCAAATACAAAAGATTTAAGAGACTGGGTACCC
ACTTCAGAGGGTGAACATACAGTTGGAATTTCCATTCACTCCACAGTTAGAG
AACAGTAGAAATGAGTTTCTATCAGGCATGCTCTGGGAGTTCACGGAGGCCC
CTGGCTCTAGTTTTGTGTTGTCAGGGAGATGTTGATCAAGCACCTTGGAAGTG
AAAAAGCAATGTCCTCTACCTGTTCCCTGGATTCTTCTCTCTTTAGACCTGTCA
CCTTGAAGAAAGCATGATCGATTCCAAACATCACTGTAGGCAAATCACCATA
GTACTTGAACTGAGTTACTGTGAAGAAAGCATGTCATCCTTGACAATGGATT
AAATGAAAGTGAGCTAATGCATGCCA

TTTTTTGTGTAAATCTAGCATTTATTGAGTGTCTGCTTTGTGCTCAGCACTGCT CAAACACTGTGAGCAAATACAAAAGATTTAAGAGACTGGGTACCCACTTCAG AGGGTGAACATACAGTTGGAATTTCCATTCACTCCACAGTTAGAGAACAGTA GAAATGAGTTTCTATCAGGCATGC

GGGGGGAGGTGTGCGATCCCTCAGCCTGGGAGTTCTACGACGCGAGGA
CTTCAGGGTCAAGCAGTGTACCTCTGTGAACATGGAGGACTTGGTGATAGCG
CACCACGGAATGGGCCACATCCACTATTTCATGCAGTACAAAGACTTACCCC
TGACTTTCCGGGAGAGTGCCAACCCTGGTTTTCATNAAGCTATTCGAGATATA
ATGGCTCTCTCAGTGTCTACCCCCAAGCATCTATACAGTCTCAACCTGCTTAG
CACTAAGGGCACTGGCTACGAGTATGACATCAACTTTCTAATGAAGATGGCC
CTCGACAAGATCGCCTTTATCCCCTTCAGCTACCTCATCGACCAGTCGCGCTC
GAGGGTCTTTGATGGAAGCATCACCAAGGAGAACTATAACCAGGAGTCCTGA
CCCTCAGCTGGAAGTATCAGGCTCTTTACCCCCAGTGCCAACACTCCAAGTG
ACTTTTACCCAGGATCCAAGTTCCACGTTCCTGCCAGCTCCCATACGTCAGCT
ACTCTGTCANCTTCATCATCAAGTTGCAGTTACACGAGGCGCTGTATCCCCAA
CAGGACACACGNGGTCCCTACACAAAATTCTAAAATCTACAATTCCAAGTAGGC
GGGAATCTCCTCGCGTATACGGAATCTGGNCTACA

TTACAGGACTGGAAAAGTATGCAACCCATAGAACCCACAGGAATGCTTATTA CTTGAGCCAGGATTGGATGAAATAATGGCGACAAGCACAGACTACAACTCTA GGCTATGGGCATGGGAGGGCTGGAGGGCTGAGGTTGGC